Journal of Capital Medical University ›› 2018, Vol. 39 ›› Issue (4): 479-485.doi: 10.3969/j.issn.1006-7795.2018.04.001
Previous Articles Next Articles
Zhang Ying1, Ruan Xiangyan1,2, Cai Guiju1, Su Yajie3, Li Na4, Alfred O. Mueck1,2
Received:
2018-05-31
Online:
2018-07-21
Published:
2018-07-21
Supported by:
CLC Number:
Zhang Ying, Ruan Xiangyan, Cai Guiju, Su Yajie, Li Na, Alfred O. Mueck. Different hormone receptors and their roles as prognostic markers in breast cancer[J]. Journal of Capital Medical University, 2018, 39(4): 479-485.
[1] Foulkes W D, Smith I E, Reis-Filho J S. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20):1938-1948. [2] Dent R, Trudeau M, Pritchard K I, et al. Triple negative breast cancer:clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15 Pt1):4429-4434. [3] 张颖, 阮祥燕, 米鑫,等. 孕激素受体膜组分1(PGRMC1)对预测乳腺癌预后作用的研究[J]. 首都医科大学学报,2015,36(4):548-552. [4] Frasor J, Danes J M, Komm B, et al.Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype[J]. Endocrinology,2003, 144(10):4562-4574. [5] Heldring N, Pike A, Andersson S, et al. Estrogen receptors:how do they signal and what are their targets[J]. Physiol Rev,2007,87(3):905-931. [6] Vrtacnik P, Ostanek B, Mencej-Bedrac S, et al. The many faces of estrogen signaling[J]. Biochem Med (Zagreb),201424(3):329-342. [7] Jensen E V, Jordan V C. The estrogen receptor:a model for molecular medicine[J]. Clin Cancer Res,2003, 9(6):1980-1989. [8] Hewitt S C, Korach K S. Estrogen receptors:structure, mechanisms and function[J]. Rev Endocr Metab Disord,2002,3(3):193-200. [9] Albanito L, Lappano R, Madeo A, et al.G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells[J]. Environ Health Perspect,2008,116(12):1648-1655. [10] Mehta R G, Hawthorne M, Mehta R R, et al. Differential roles of ER-α and ER-β in normal and neoplastic development in the mouse mammary gland[J]. PLoS One, 2014, 9(11):e113175. [11] Stope M B, Popp S L, Knabbe C, et al. Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands[J]. Breast Cancer Res Treat,2010,120(2):357-367. [12] Taylor A H, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues[J]. J Mol Endocrinol,2000, 24(1):145-155. [13] Carroll J S, Brown M. Estrogen receptor target gene:an evolving concept[J]. Mol Endocrinol, 2006,20(8):1707-1714. [14] Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B[J]. EMBO J,1990,9(5):1603-1614. [15] Soyal S, Ismail P M, Li J, et al. Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics[J]. Breast Cancer Res,2002, 4(5):191-196. [16] Conneely O M, Mulac-Jericevic B, Lydon J P. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms[J].Steroids,2003, 68(10-13):771-778. [17] Mulac-Jericevic B, Lydon J P, DeMayo F J,et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform[J]. Proc Natl Acad Sci U S A,2003,100(7):9744-9749. [18] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002,277(7):5209-5218. [19] Hopp T A, Weiss H L, Hilsenbeck S G, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates[J]. Clin Cancer Res, 2004, 10(8):2751-2760. [20] Cahill M A. Progesterone receptor membrane component 1:an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105:16-36. [21] Jeng M H, Parker C J, Jordan V C.Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation[J].Cancer Res,1992,52(23):6539-6546. [22] Neubauer H, Ruan X, Schneck H.Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J].Menopause,2013,20(5):504-510. [23] Ruan X,Neubauer H,Yang Y. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J].Climacteric,2012,15(5):467-472. [24] AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012:cancer in children and adolescents[J]. Epidemiol Prev,2013,37(1 Suppl 1):1-225. [25] McDonnell D P, Chang C Y, Nelson E R. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer[J].Climacteric, 2014,17 Suppl 2:60-65. [26] Kuiper G G, Carlsson B, Grandien K,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta[J]. Endocrinology, 1997, 138(3):863-870. [27] Guo L, Meng J, Yilamu D, et al. Significance of ER-β expression in different molecular subtypes of breast cancer[J]. Diagn Pathol,2014,9:20. [28] Ignatiadis M, Sotiriou C. Luminal breast cancer:from biology to treatment[J]. Nat Rev Clin Oncol,2013,10(9):494-506. [29] Skliris G P, Leygue E, Curtis-Snell L, et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours[J]. Br J Cancer,2006,95(5):616-626. [30] Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1(ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)[J]. Ann Oncol,2013,24(8):1986-1993. [31] Liu J, Guo H, Mao K,et al. Impact of estrogen receptor-β expression on breast cancer prognosis:a meta-analysis[J]. Breast Cancer Res Treat,2016,156(1):149-162. [32] Wu X, Subramaniam M, Grygo S B,et al. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen[J]. Breast Cancer Res,2011,13(2):R27. [33] Elebro K, Borgquist S, Simonsson M,et al. Combined androgen and estrogen receptor status in breast cancer:treatment prediction and prognosis in a population-based prospective cohort[J]. Clin Cancer Res,2015,21(16):3640-3650. [34] Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J]. J Clin Oncol,2005,23(30):7721-7735. [35] Bardou V J, Arpino G, Elledge R M, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. J Clin Oncol,2003,21(10):1973-1979. [36] Bae S Y, Kim S, Lee J H, et al. Poor prognosis of single hormone receptor-positive breast cancer:similar outcome as triple-negative breast cancer[J]. BMC Cancer,2015,15:138. [37] Yang L H, Tseng H S, Lin C, et al. Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients[J]. J Breast Cancer,2012, 15(3):288-295. [38] Richer J K, Jacobsen B M, Manning N G, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells[J]. J Biol Chem,2002, 277(7):5209-5218. [39] Bamberger A M, Milde-Langosch K, Schulte H M, et al. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer:correlations with clinicopathologic tumor parameters and expression of AP-1 factors[J]. Horm Res, 2000, 54(1):32-37. [40] 杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582. [41] 郑红梅,李祥,金立亭,等.三阴性乳腺癌基因学分子分型和个体化治疗新进展[J].中华肿瘤防治杂志, 2016,23(17):1198-1204. [42] Aydiner A, Sen F, Tambas M,et al. Metaplastic breast carcinoma versus triple-negative breast cancer:survival and response to treatment[J].Medicine (Baltimore),2015,94(52):e2341. [43] Neubauer H,Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J].Menopause,2011,18(8):845-850. [44] Neubauer H, Chen R, Schneck H, et al.Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J].Horm Mol Biol Clin Investig,2011,6(1):185-192. [45] Zhang Y, Ruan X, Willibale M, et al. May progesterone receptor memebrane component 1(PGRMC1) predict the risk of breast cancer?[J].Gynecol Endocrinol, 2016,32(1):58-60. [46] 王利娟,阮祥燕,赵越.PGRMC1在乳腺癌组织中的表达及其与临床病理特征的相关性[J].首都医科大学学报,2018,39(2):272-276. [47] Thomas P, Pang Y, Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1(PGRMC1):evidence for a role of PGRMC1 as an adaptor protein for steroid receptors[J]. Endocrinology, 2014,155(3):1107-1119. [48] Peluso J J,Pappalardo A,Losel R,et al.Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries:PAIRBP1 regulation of granulosa and luteal cell viability[J].Biol Reprod,2005,73(2):261-270. [49] Crudden G, Chitti R E, Craven R J.Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J].J Pharmacol Exp Ther, 2006,316(1):448-455. [50] Ruan X, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor memebrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J].Menopause,2017,24(2):203-209. [51] Clark N C, Friel A M, Pru C A, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther, 2016,17(3):262-271. [52] Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:a brief Summary of the consensus discussion[J]. 2015,10(2):124-130. [53] Otsuka I, Takahashi S, O'uchi K, et al.Clinicopathological features of endometrial carcinoma in tamoxifen-and toremifene-treated breast cancer patients[J].Gan To Kagaku Ryoho,2010,37(2):279-283. [54] Leung F, Terzibachian J J, Govyadovskiy A, et al.Tamoxifen in the adjuvant setting for breast cancer:reflexions about the risk of uterine carcinosarcoma[J]. Gynecol Obstet Fertil,2009,37(5):447-451. [55] Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS)[J]. Acta Obstet Gynecol Scand,2012,91(1):3-9. [56] Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy:a clinical review[J]. Climacteric, 2015,18(4):470-482. [57] Dominick S, Hickey M, Chin J,et al. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Database Syst Rev,2015,(12):CD007245. [58] Trinh X B, Tjalma W A, Makar A P, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril,2008,90(1):17-22. [59] Fu Y, Zhuang Z.Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients:a meta-analysis[J].Int J Clin Exp Pathol,2014,7(10):6419-6429. |
[1] | Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters [J]. Journal of Capital Medical University, 2022, 43(3): 350-356. |
[2] | Wei Changsheng, Luo Chengyu, Zhang Shuqi. Application of periareolar incision combined with mastoscopic axillary lymph node dissection in breast conserving surgery for early breast cancer [J]. Journal of Capital Medical University, 2021, 42(6): 1014-1020. |
[3] | Ruan Xiangyan, Yang Yu, Lu Dan, Du Juan, Cheng Jiaojiao, Gu Muqing, Li Yanglu, Jin Fengyu, Duan Wei, Dai Yinmei, Ju Rui, Xu Xin, Matthias Korell, Alfred O. Mueck. The first successful case report of breast cancer patient's cryopreserved ovarian tissue transplantation in China and literature review [J]. Journal of Capital Medical University, 2021, 42(2): 177-182. |
[4] | Yang Yang, Kang Hua, Zhao Jing, Ling Yuwei, Zhao Ye, Wang Yajun, Rong Dongdong. Retrospective analysis of preoperative breast MRI of breast cancer patients with breast conserving surgery [J]. Journal of Capital Medical University, 2020, 41(6): 943-953. |
[5] | Wang Aiting, Yan Dan, Qi Xianrong. Evaluation of the inhibitory effect of docetaxel-loaded polymeric micelles on breast cancer metastasis in mice [J]. Journal of Capital Medical University, 2020, 41(2): 225-230. |
[6] | Wang Wei, Zhang Zihan, Zhai Yan, Sang Cuiqin, Wang Shuzhen. Clinical characteristics of the double primary malignant tumors of uterine corpus/breast [J]. Journal of Capital Medical University, 2019, 40(6): 857-862. |
[7] | Zhang Yunxian, Wang Yamei, Zhou Ping. Construction and functional analysis of circular RNA interaction network based on open chromatin in breast cancer [J]. Journal of Capital Medical University, 2019, 40(6): 901-910. |
[8] | Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients [J]. Journal of Capital Medical University, 2019, 40(6): 911-915. |
[9] | Zhang Lingyan, Ruan Xiangyan, Cai Guiju, Gu Muqing, Alfred O. Mueck. Effect of tamoxifen on Ki-67 expression in breast tumor tissue of nude mice transfected with progesterone receptor membrane component 1 [J]. Journal of Capital Medical University, 2019, 40(4): 533-538. |
[10] | Wang Yuejiao, Ruan Xiangyan, Gu Muqing, Cai Guiju, Li Xue, Zhang Lingyan, Alfred O. Mueck. Tamoxifen treated breast cancer xenograft in nude mice and uterine pathological changes [J]. Journal of Capital Medical University, 2019, 40(4): 539-543. |
[11] | Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients [J]. Journal of Capital Medical University, 2019, 40(3): 443-448. |
[12] | Chen Nina, Fan Yichang, Shang Kun, Yang Jing, Cao Bangwei. Serum lipid and apolipoprotein levels were associated to the Ki-67 and molecular classification of breast cancer [J]. Journal of Capital Medical University, 2019, 40(2): 191-194. |
[13] | Li Xue, Ruan Xiangyan, Gu Muqing, Cai Guiju, Zhao Yue, Alfred O. Meuck. Progesterone receptor membrane component 1 increases hormone induced proliferation of breast cancer cells——E2 vs sequential combination vs continuous combination [J]. Journal of Capital Medical University, 2019, 40(2): 237-243. |
[14] | Xu Quan, Liu Yujie, Pan Yu, Zheng Xiuyuan, Liu Jingmin, Sun Xiaohua, Zou Lili, Ma Lina, Yan Hongsong. Effects of bioelectrical impedance test frequency on quantitative assessment of breast cancer associated lymphedema [J]. Journal of Capital Medical University, 2018, 39(5): 747-751. |
[15] | Zhao Yue, Ruan Xiangyan, Zhang Quandong, Wang Husheng, Li Xue, Cai Guiju, Gu Muqing, Alfred O. Mueck. Correlation between the blood membrane-bound progesterone level and clinical application in patients with breast cancer [J]. Journal of Capital Medical University, 2018, 39(4): 486-493. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||